Abstract-In a randomized, double-blinded, controlled clinical trial, participants with peripheral arterial disease (75% hypertensive) consumed 30 g of milled flaxseed/d for 6 months. The flaxseed group exhibited significant reductions in systolic (−10 mm Hg) and diastolic (−7 mm Hg) blood pressure. Flaxseed contains the n3 fatty acid α-linolenic acid. Plasma α-linolenic acid increased with ingestion of flaxseed and was inversely associated with blood pressure. However, the antihypertensive mechanism was unclear. Oxylipins derived from polyunsaturated fatty acids regulate vascular tone. Therefore, the objective was to examine whether flaxseed consumption altered plasma oxylipins in a manner that influenced blood pressure. Plasma of FlaxPAD (Flaxseed for Peripheral Arterial Disease) participants underwent solid phase extraction and high-performance liquid chromatography-mass spectrometry/mass spectrometry analysis. The flaxseed group exhibited significant decreases in 8 plasma oxylipins versus control. Six of these (5,6-, 8,9-, 11,12-, 14,15- 
T he World Health Organization identified high blood pressure as a global public crisis because it is the leading risk factor attributed to death worldwide. 1 Globally, 40% of individuals have hypertension, and a significant proportion of individuals are undiagnosed, untreated, or have uncontrolled high blood pressure. 1 Therefore, it is important to identify effective and desirable treatment strategies to reduce the prevalence and incidence of hypertension globally.
A potential therapeutic strategy for high blood pressure may be through dietary intervention. Recently, patients with peripheral arterial disease (PAD; 75% with hypertension) who consumed 30 g of milled flaxseed daily for 6 months exhibited significant reductions in systolic (−10 mm Hg) and diastolic (−7 mm Hg) blood pressure (the Flaxseed for Peripheral Arterial Disease [FlaxPAD] Trial). 2 Flaxseed contains the n3 fatty acid α-linolenic acid (ALA), lignans, and fiber. The participants consuming flaxseed exhibited significant increases in plasma ALA and enterolignans, which were inversely associated with blood pressure. 2 However, the biological mechanism of action responsible for the blood pressure-lowering effects was unclear.
Oxylipins are a class of highly bioactive molecules that include the octadecanoids, eicosanoids, and docosanoids.
Oxylipins are derived endogenously from polyunsaturated fatty acids. Because plasma concentrations of the polyunsaturated fatty acids, ALA and eicosapentaenoic acid, increased in the flax group, 2 we hypothesized that concentrations of oxylipins also changed. Oxylipins have a fundamental role in regulating vascular tone and inflammation. For example, some oxylipins produced from arachidonic acid or linoleic acid have been associated with inflammation, [3] [4] [5] tissue damage, 6, 7 vasoconstriction, 8, 9 and oxidative stress. 10 In contrast, the epoxyeicosatrienoic acids (EETs) produced from arachidonic acid are endothelial-derived hyperpolarizing factors that are associated with vasodilation and natriuresis 11, 12 and may indirectly propagate vasodilation [13] [14] [15] by activating endothelial nitric oxide synthase. 16, 17 EETs can be rapidly metabolized to dihydroxyeicosatrienoic acids (DHETs) by the enzyme soluble epoxide hydrolase (sEH), resulting in a concomitant loss of vasodilation. 18, 19 sEH also converts the protoxins, epoxyoctadecenoic acids, to the dihydroxyoctadecenoic acids, which are potent cytotoxic and proinflammatory metabolites. [20] [21] [22] Because products of sEH propagate loss of vascular relaxation and promote inflammation, targeting sEH inhibition pharmacologically has been used successfully to reduce blood pressure, 12, 17, 23 hypertension-associated renal damage, 17 and infarction size 23 in animal models. The proposed relationship between epoxygenase-derived oxylipins and hypertension is depicted in Figure 1 .
To test the hypothesis that flaxseed decreased the levels of oxylipins associated with inflammation and vasoconstriction, the study objectives were 3-fold: (1) to characterize and quantify the plasma oxylipin profile of participants with PAD, (2) to compare changes in plasma oxylipin concentrations in the control and flaxseed groups, and (3) to determine the mechanism whereby any changes in oxylipins may have influenced blood pressure in the FlaxPAD Trial.
Methods

Participants and Food Products
A randomized, double-blinded, parallel, controlled clinical trial was established to determine the cardiovascular effects of dietary flaxseed in patients with PAD. 24 Seventy-five percent of the participants were diagnosed as hypertensive at baseline (blood pressure ≥140/90 mm Hg). 2, 24 Participants (n=110) consumed food products containing either 30 g of milled flaxseed (treatment) or a combination of mixed dietary oils, milled wheat, and bran (control) for 6 months. Further details of the food product composition, 25, 26 participant enrollment, intervention allocation, clinical characteristics, and blood pressure outcomes have been previously published. 2, 24 The trial is available at http://www.clinicaltrials.gov/ct2/show/NCT00781950?term=grant+p ierce+flax&rank=1.
All participants provided informed consent, and all procedures were performed according to institutional guidelines. The trial was approved by Health Canada and its Natural Health Product Directorate, the University of Manitoba Research Ethics Board, and the St Boniface Hospital Research Review Committee.
Oxylipin Analysis
Blood from baseline and 6 months was collected into EDTA tubes and centrifuged at 4°C to isolate the plasma fraction and stored at −80°C. A total of 98 participants at baseline and 76 participants at 6 months had adequate plasma remaining for oxylipin analysis (200 μL). The oxylipin extraction and analysis methodology have been previously published 27, 28 and are included in the online-only Data Supplement (Table S1 in the online-only Data Supplement). Quantification of oxylipins was determined using the stable isotope dilution method 29 and expressed as nmol/L.
sEH Percent Inhibition
The Soluble Epoxide Hydrolase Inhibitor Screening Assay Kit from Cayman Chemical (item no. 10011671, Ann Arbor, MI) was used to determine the influence of flaxseed bioactives or patient plasma lipid extract on sEH activity. Lipid extraction of patient plasma was performed according to the Folch method. 30 ALA (Nu-Chek Prep Inc, MN, item no. U-62-A), enterodiol (Sigma Aldrich Oakville, Ontario, Canada, item no. 45 198), and enterolactone (Sigma Aldrich Oakville, Ontario, Canada, item no. 45 199) were tested for their relationship to sEH activity. Linoleic acid (Nu-Chek Prep Inc, MN, item no. U-59-A) was assessed as a potential negative control because linoleic acid concentrations did not change in either the flax or placebo group throughout the trial. Six physiological concentrations of each compound were used within the minimum and maximum plasma concentrations observed in the current population.
Inflammatory Markers
C-reactive protein, monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin-10 were quantified in plasma using a Multiplex technology (Milliplex Cytokine/Chemokine magnetic bead panel, performed on Luminex MAGPIX, Millipore, Billerica, MA). C-reactive protein was quantified using a WideScreen Human CVD Panel (EMD Millipore, Billerica, MA) and performed on BioPlex 200 (Bio-Rad Laboratories, Hercules, CA). Plasma samples were prepared according to the commercial protocols established for the Multiplex assay system. 
Statistical Analysis
Data were assessed for normality and homogeneity of variance using Shapiro-Wilk and Levene test, respectively. The data were analyzed with multiple 2-sided Mann-Whitney U tests to assess differences between groups or time points. Because of multiple testing, P values were corrected with the false discovery rate correction. sEH inhibition data ( Figure 3 ) were analyzed using Spearman correlation. Sample sizes for each analysis are provided within tables and figures. Data are represented as mean±95% confidence intervals.
Results
Absolute Plasma Oxylipin Concentrations
The plasma oxylipin concentrations of patients with PAD were quantified before and after dietary intervention (Table  S2 ). Baseline plasma oxylipin profiles did not differ between the flaxseed and control group. After 6 months of dietary intervention, 6 oxylipins were significantly different between the control and flaxseed group (P<0.05). The ALA-derived 9-hydroxyoctadecatrieonic acid was significantly higher in the flax versus placebo group at 6 months. 11,12-DHET, 14,15-DHET, 4-hydroxydocosahexanoic acid (HDOHE), 20-HDOHE, and 19,20-dihydroxydocosapentanoic acid were significantly lower in the flax versus placebo group at 6 months. By comparison of time, the control group did not exhibit any significant differences in the absolute concentrations of plasma oxylipins from baseline to 6 months. The flax group exhibited a significantly lower concentration only in 14,15-DHET at 6 months versus baseline (Table S2) .
Change in Plasma Oxylipin Concentrations
Change in plasma oxylipin concentrations were calculated for those individuals who provided blood samples at baseline and 6 months with an adequate volume of plasma of ≥200 μL (n=76). Nine plasma oxylipins were significantly different between the control and flax group for change from baseline to 6 months (P<0. 
Association Between Change in sEH-Derived Oxylipins and Change in Blood Pressure
A reduction in total plasma sEH-derived oxylipins was associated with a reduction in systolic blood pressure (−7.97 [−14.4 to −1.50] mm Hg). This was significantly different from those who exhibited an increase in total plasma sEH products who on average exhibited an increase in systolic blood pressure (+3.17 [−4.78 to 11.1] mm Hg; P=0.048). Change in diastolic blood pressure or mean arterial pressure were not significantly influenced by a change in total plasma sEH-derived oxylipins (P=0.28 and 0.11, respectively; Figure 3 ). When the change in sEH-derived oxylipins was grouped by DHETs and dihydroxyoctadecenoic acids, there was no significant association to change in blood pressure (P>0.05). On analysis of individual sEH-derived oxylipins, 9,10-dihydroxyoctadecenoic acid and 8,9-DHET were significantly associated with change in systolic blood pressure (P=0.048 and 0.035, respectively) and mean arterial pressure (P=0.035 and 0.035, respectively; Figure 3 ).
Inhibition of sEH
A strong inverse relationship was observed for ALA and % initial activity of sEH (P=0.0048; ρ=−0.94; Figure 4 ). From Figure 2 . Change in plasma concentrations of soluble epoxide hydrolase-derived oxylipins in the control and flax group from baseline to 6 months. Data are represented as mean±95% confidence limit (n=76). Data were analyzed using multiple pair wise Mann-Whitney U and the false discovery rate correction (P≤0.050). *Control and flax group differed significantly (P≤0.050). DHET indicates dihydroxyeicosatrienoic acid; and DiHOME, dihydroxyoctadecenoic acid. the lowest ALA concentration (0.0075 mg/mL) to the highest (0.11 mg/mL), % initial activity of sEH declined from 43% to 12%. By contrast, enterodiol (P=0.27), enterolactone (P=0.87), and linoleic acid (P=0.62) were not significantly associated with sEH activity (Figure 4) .
Because increasing concentrations of ALA lowered sEH activity in the assay, it was hypothesized that plasma from patients in the flax group who had higher ALA concentrations by 6 months should lower sEH activity more than plasma from patients in the placebo group who had lower ALA concentrations. ALA concentrations in randomly selected plasma samples from patients (n=5/group) in the placebo group were 0.037±0.008 mg/mL at baseline and 0.021±0.007 mg/mL at 6 months. ALA concentrations in plasma samples from patients (n=5/group) in the flax group were 0.024±0.006 mg/mL at baseline and 0.067±0.0060 mg/mL at 6 months. Lipid extracts from these plasma samples were applied to the sEH assay to determine whether the patient plasma could inhibit sEH activity. Percent initial activity of sEH fell by −10.2% (−30.7% to 10.3%) from baseline to 6 months in the flax group and by only −3.10% (−13.6% to 7.44%) from baseline to 6 months in the placebo group. Although this did not achieve statistical significance, the trend for the response was consistent with the hypothesis that ALA can inhibit sEH activity (P=0.13).
Interestingly, the change in plasma ALA concentration from 0.024 to 0.067 mg/mL in the flax group demonstrated the same 10% decrease in sEH activity as obtained in Figure 4 using 0.0375 to 0.075 mg/mL ALA.
Inflammatory Markers
Plasma C-reactive protein, monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin-10 did not differ significantly by group or time point (Table) . None of the inflammatory markers were significantly associated with the sEH-derived oxylipins (P>0.05).
Discussion
The ingestion of flaxseed in the FlaxPAD Trial resulted in a large decrease in systolic and diastolic blood pressure in patients with PAD and hypertension. 2 Identifying the biological mechanism for this effect is critical to provide confidence in the antihypertensive action and insight into therapeutic targets. The present data provide evidence that consumption of flaxseed may reduce blood pressure by altering the plasma oxylipin profile via an inhibition of sEH. All 6 of the sEH-derived oxylipins detected significantly decreased in the flax group and increased in the control (Figure 1) . Change in systolic, diastolic, and mean arterial pressure (mm Hg) by change in plasma soluble epoxide hydrolase (sEH)-derived oxylipins. Data are represented as mean±95% confidence limit (n=76). Data were analyzed using multiple pairwise Mann-Whitney U and the false discovery rate correction. *Significant difference (P≤0.050) between groups (ie, those who exhibited a decrease vs those who exhibited an increase in that particular oxylipin or group of oxylipins). DHET indicates dihydroxyeicosatrienoic acid; and DiHOME, dihydroxyoctadecenoic acid. by guest on October 30, 2017 http://hyper.ahajournals.org/
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The relationship between sEH-derived oxylipins and blood pressure was confirmed by the positive relationship between sEH-derived oxylipins and systolic blood pressure. More specifically, the reductions in plasma 9,10-dihydroxyoctadecenoic acid and 8,9-DHET were strongly associated with reductions in systolic and mean arterial blood pressure. A similar trend existed for a positive relationship between sEH products and diastolic blood pressure, but this did not achieve statistical significance. A larger sample size may have been required to detect a significant difference. The relatively small reduction in diastolic blood pressure in comparison with systolic and mean arterial pressure may also have made it more difficult to detect a significant difference.
Because the flaxseed group exhibited significant reductions in all sEH-derived oxylipins detected, it is reasonable to hypothesize that a bioactive component of flaxseed inhibited sEH. Of the flaxseed bioactives tested, ALA had the only significant relationship with sEH activity (Figure 4 ). This data are the first to demonstrate an n3 fatty acid inhibiting sEH. Using lipid extracts from plasma obtained from the placebo and flax groups, the same trend was shown consistent with the hypothesis that plasma ALA had the capacity to lower sEH activity. However, these results warrant further investigation in an in vivo animal model or in human tissue biopsy samples where sEH protein levels and sEH activity can be quantified. Figure 5 represents the hypothesized ALA-induced alteration of the oxylipin profile and the influence on blood pressure.
The association between sEH-derived oxylipins and blood pressure in the current trial is consistent with previous animal studies. Pharmacological inhibition of sEH has resulted in a reduction of sEH-derived DHETs and blood pressure in animal studies. 17, 23, 31, 32 The potential mechanisms behind the relationship between sEH-derived oxylipins and blood pressure are numerous. The sEH substrates, EETs, have known vasodilatory actions. [12] [13] [14] [15] [16] [17] [18] [19] 23 However, because of the short half-life of EETs, 33 these sEH substrates were below the level of detection and it was not possible to confirm whether EETs increased in the patient population. Despite this, it is well established that the products of sEH have deleterious effects, [18] [19] [20] [21] [22] and a decrease in sEH products may provide protection against vasoconstriction and inflammation. Interestingly, C-reactive protein concentrations decreased to half the baseline concentration by 6 months in the flax group. However, none of the inflammatory markers achieved statistical significance. This could have been because of the large variation observed in this population. The above hypothesis for a mechanism of antihypertensive action does not discount the possibility that other oxylipins may have contributed as well. For example, reductions in docosahexanoic acid-derived 19,20-dihydroxydocosapentanoic acid and 20-HDOHE were observed in the flax group. Notably, although the biological actions of 19,20-dihydroxydocosapentanoic acid are unknown, it is also thought to be an sEH product. 34, 35 By contrast, an increase in the n3 fatty acid-derived 4-HDOHE and 9-hydroxyoctadecatrienoic acid was observed in the flax group. However, the influence of these oxylipins on vascular tone or blood pressure has yet to be investigated.
Implications and Future Directions
The data in the present study provide evidence for the antihypertensive effects of dietary flaxseed to be through an alteration in oxylipins that may be induced via an ALA-mediated inhibition of sEH. This knowledge lays the foundation to investigate further the influence of ALA on hypertension in both clinical settings and animal models. Most importantly, the data provide important mechanistic information to explain partially the significant antihypertensive action of dietary flaxseed 2 and ALA, 36 which may be a desirable and effective treatment strategy for patients with hypertension.
Perspectives
The antihypertensive effects of dietary flaxseed are potent for patients with hypertension. 2 The ALA content of flaxseed may provide this antihypertensive effect partly through an alteration of the oxylipin profile via an inhibition of sEH. This enzyme has been identified in animal work as an antihypertensive target. Our work now supports this assertion and identifies the potential of ALA as a natural inhibitor of the enzyme. In view of the growing risk of hypertension as a burden of death today in most of the world, 1 and the rising economic burden of the disease, 2 having a nutritional strategy available as a complimentary approach is significant. Identifying the biological mechanism adds confidence to the antihypertensive actions of dietary flaxseed. 
Methods
Oxylipin Extraction and Analysis
To isolate the oxylipins, 200 µL of plasma were diluted with 800 µL of water acidified to a pH of 3 with hydrochloric acid. The sample pH was brought to 3 with the addition of hydrochloric acid. Strata-X, 33 μm, polymeric reversed phase columns (Phenomenex, product no. 8B-S100-UBL) were conditioned with 2 mL of LC-MS grade methanol followed by 2 mL of pH 3 water. The sample was applied to the column followed by a 10% methanol in pH 3 water wash that was rinsed from the tube previously holding the sample. To elute, 2 mL of LC-MS grade methanol were added to the column. This eluate was then dried under a nitrogen evaporator set to 37°C and reconstituted with 120 μL of solvent A (water:acetonitrile:formic acid (70:30:0.02 v/v/v LC-MS grade). The analytes were separated with high performance liquid chromatography and tandem mass spectrometry (AB SCIEX 4000 QTRAP) using a Luna 5 μm C18 (2) (Phenomenex -product no. 00G-4252-B0), 250 x 2.0mm column and multiple reaction monitoring. Details of the deuterated internal standards, collision-induced dissociation mass transitions, retention times, and detector response factors for analytes are provided in Table 1 of the Online Supplemental Material. The quantification limit was set at 3 levels above the background. 
